Study on primary central nervous system lymphoma in pediatric patients.
Clinical features
Demographic
Pediatric
Primary central nervous system lymphoma
Treatment strategy
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
06
05
2022
accepted:
09
06
2023
medline:
1
8
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
Primary central nervous system lymphoma (PCNSL) in pediatric patients presents diagnostic and treatment challenges, leading to delays and suboptimal strategies. Moreover, PCNSL in immunocompetent pediatric patients is rarely reported. This retrospective study aimed to describe the demographic and clinical features, as well as outcomes, of pediatric PCNSL cases. A retrospective review was conducted on 11 immunocompetent pediatric patients diagnosed with PCNSL between January 2012 and April 2020. Data regarding age, gender, initial presenting symptoms, tumor location, and radiological characteristics were collected. Treatment strategies and analyzed prognosis were documented. Survival curves were generated using the Kaplan-Meir method, and data were analyzed using SPSS (version 23.0, IBM Corp.). The study cohort comprised 11 patients, including 10 males and 1 female. The age at diagnosis ranged from 4 to 15 years, with a median age of 10.6 years. Headache was the most common presenting symptom, observed in 81.8% (9/11) of patients. Tumor locations in the supratentorial and infratentorial regions exhibited a similar occurrence rate. All tumors showed strong contrast enhancement on T1-weighted images. The average survival time for the 11 patients was 44.4 months. Among them, 5 patients died by the last follow-up visit, with a mean survival time of 8.8 months (one patient died in a car accident). Headache is the predominant manifestation of PCNSL in pediatric patients. PCNSL demonstrates imaging characteristics resembling various intracranial tumors and is associated with a poor prognosis. Therefore, pediatric neurosurgeons should exercise caution in diagnosing and treating intracranial lymphoma.
Sections du résumé
BACKGROUND
Primary central nervous system lymphoma (PCNSL) in pediatric patients presents diagnostic and treatment challenges, leading to delays and suboptimal strategies. Moreover, PCNSL in immunocompetent pediatric patients is rarely reported. This retrospective study aimed to describe the demographic and clinical features, as well as outcomes, of pediatric PCNSL cases.
METHODS
A retrospective review was conducted on 11 immunocompetent pediatric patients diagnosed with PCNSL between January 2012 and April 2020. Data regarding age, gender, initial presenting symptoms, tumor location, and radiological characteristics were collected. Treatment strategies and analyzed prognosis were documented. Survival curves were generated using the Kaplan-Meir method, and data were analyzed using SPSS (version 23.0, IBM Corp.).
RESULTS
The study cohort comprised 11 patients, including 10 males and 1 female. The age at diagnosis ranged from 4 to 15 years, with a median age of 10.6 years. Headache was the most common presenting symptom, observed in 81.8% (9/11) of patients. Tumor locations in the supratentorial and infratentorial regions exhibited a similar occurrence rate. All tumors showed strong contrast enhancement on T1-weighted images. The average survival time for the 11 patients was 44.4 months. Among them, 5 patients died by the last follow-up visit, with a mean survival time of 8.8 months (one patient died in a car accident).
CONCLUSION
Headache is the predominant manifestation of PCNSL in pediatric patients. PCNSL demonstrates imaging characteristics resembling various intracranial tumors and is associated with a poor prognosis. Therefore, pediatric neurosurgeons should exercise caution in diagnosing and treating intracranial lymphoma.
Identifiants
pubmed: 37401975
doi: 10.1007/s00381-023-06021-z
pii: 10.1007/s00381-023-06021-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2037-2043Subventions
Organisme : This research is funded by the National Natural Science Foundation of China
ID : No.81870834
Organisme : National Natural Science Foundation of China
ID : No.62276027
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18(17):3144–50
doi: 10.1200/JCO.2000.18.17.3144
pubmed: 10963643
Wang H et al (2018) Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre. J Int Med Res 46(2):883–894
doi: 10.1177/0300060517734395
pubmed: 28984175
Baleydier F et al (2001) Primary lymphoma of the pituitary stalk in an immunocompetent 9-year-old child. Med Pediatr Oncol 36(3):392–5
doi: 10.1002/mpo.1094
pubmed: 11241445
Kudrimoti JK et al (2015) Primary dural non-hodgkin’s lymphoma mimicking meningioma: A case report and review of literature. J Cancer Res Ther 11(3):648
doi: 10.4103/0973-1482.146112
pubmed: 26458614
Ostrom QT et al (2016) American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 18(Suppl 1):i1-i50
Masouris I et al (2021) CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma-Diagnostic, Therapeutic, and Prognostic Relevance. Front Neurol 12
Alvarez-Pinzon AM et al (2021) Gamma knife stereotactic radiosurgery as an effective tool in primary CNS lymphoma: Evaluation of stereotactic radiosurgery and methotrexate treatment in a prospective and observational clinical research study. Clin Neurol Neurosurg 201
Attarbaschi A et al (2019) Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents. Blood Adv 3(24):4291–4297
doi: 10.1182/bloodadvances.2019001062
pubmed: 31869415
pmcid: 6929389
Decavèle M et al (2021) Clinical features and outcome of patients with primary central nervous system lymphoma admitted to the intensive care unit: a French national expert center experience. J Neurol 268(6):2141–2150
doi: 10.1007/s00415-021-10396-x
pubmed: 33452932
pmcid: 7810601
Nagarajan E et al (2020) Primary Central Nervous System Lymphoma Presenting as Parkinsonism with Atypical MRI Findings and Elevated 14-3-3 Protein. J Neurosci Rural Prac 11(03):492–494
doi: 10.1055/s-0040-1713300
Ouyang TH et al (2020) Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma. World Neurosurg 139:E508–E516
doi: 10.1016/j.wneu.2020.04.049
pubmed: 32311566
Tsang M, Cleveland J, Rubenstein JL (2020) On point in primary CNS lymphoma. Hematol Oncol 38(5):640–647
doi: 10.1002/hon.2761
pubmed: 32510610
pmcid: 8815361
Garth R, Coddington R, Brightwell A (1993) Primary cerebral lymphoma presenting with bilateral cerebellopontine angle lesions. J Laryngol Otol 107(10):937–939
doi: 10.1017/S0022215100124843
pubmed: 8263396
Grommes C, DeAngelis LM (2017) Primary CNS Lymphoma. J Clin Oncol 35(21):2410–2418
doi: 10.1200/JCO.2017.72.7602
pubmed: 28640701
pmcid: 5516483
Han CH, Batchelor TT (2017) Diagnosis and management of primary central nervous system lymphoma. Cancer 123(22):4314–4324
doi: 10.1002/cncr.30965
pubmed: 28950405
Calimeri T et al (2021) How we treat primary central nervous system lymphoma. ESMO Open 6(4):100213
doi: 10.1016/j.esmoop.2021.100213
pubmed: 34271311
pmcid: 8287145
Korfel A (2015) A focus on pharmacotherapy for primary central nervous system lymphoma. Expert Rev Hematol 8(5):559–62
doi: 10.1586/17474086.2015.1066672
pubmed: 26159859
Holdhoff M et al (2014) High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 83(3):235–9
doi: 10.1212/WNL.0000000000000593
pubmed: 24928128
pmcid: 4117362
Farah RA et al (2020) Primary Central Nervous System Lymphoma in a Patient on Adalimumab Therapy for Chronic Plaque Psoriasis. World Neurosurg 139:260–263
doi: 10.1016/j.wneu.2020.03.155
pubmed: 32247793
Ling SM et al (1994) Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer 73(10):2570-82
Nelson DF (1999) Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neuro-oncol 43(3):241–247
doi: 10.1023/A:1006206602918
Wang XX et al (2014) Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience. Leuk Lymphoma 55(11):2497–501
doi: 10.3109/10428194.2014.889823
pubmed: 24605911
Schaff LR, Grommes C (2021) Update on Novel Therapeutics for Primary CNS Lymphoma. Cancers (Basel) 13(21)
Taylor AMR et al (2019) Chromosome instability syndromes. Nat Rev Dis Primers 5(1):64
doi: 10.1038/s41572-019-0113-0
pubmed: 31537806
Dörr JR et al (2021) Germline Mutations Including the Rare Pathogenic Variant c.3206delC in the ATM Gene Cause Ataxia Teleangiectasia-Associated Primary Central Nervous System Lymphoma. Children (Basel) 8(6)
Schneider K et al (1993) Li-Fraumeni Syndrome, in GeneReviews
Ferner RE, Gutmann DH (2013) Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol 115:939–55
doi: 10.1016/B978-0-444-52902-2.00053-9
pubmed: 23931823
Kaulen LD et al (2019) Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. J Neurooncol 144(1):107–115
doi: 10.1007/s11060-019-03208-w
pubmed: 31190317
Choi CY, Lee CH, Joo M (2013) Lymphomatosis cerebri. J Korean Neurosurg Soc 54(5):420–2
doi: 10.3340/jkns.2013.54.5.420
pubmed: 24379950
pmcid: 3873356